2018 Annual Report: Top 50 Companies – Looking to future challenges
The top pharmaceutical companies are trying to proactively tackle, through shifts in R&D strategy and other tactics, the healthcare demands of the future.
Featured Posts
2018 Annual Report: Top 50 Companies – Looking to future challenges
The top pharmaceutical companies are trying to proactively tackle, through shifts in R&D strategy and other tactics, the healthcare demands of the future.
Company of the Year 2018 — Johnson & Johnson: Defining the future of healthcare
The executive management team of this “132-year-old startup” company is excited about a future that lies beyond the intersection of science and technology.
Top 200 Medicines Annual Report 2018: Blockbusters thriving despite tumultuous climate
There were as many billion-dollar brands in 2017 as there have been in any other calendar year despite the cratering effects of massive patent cliffs in 2012 and 2015.
Annual Report 2018: State of the Bio Industry
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
2018 Annual Report: Healthcare Communications Agencies Overview – A Year Of Steady Successes
2017 was a very good year for many of the agencies profiled in this annual directory featuring the leading healthcare communications agencies. Some reported individual setbacks, but they were still able to overcome these. As a wave of new drugs and biologics hit the market, several of the top healthcare agencies supported their launches.
Top 10 Pipelines 2018 Annual Report
Deal activity is rampant as Big Pharma gobbles up next-generation medicines and technologies to help overcome maturing pipelines and biosimilar threats.
Company of the Year 2018 — Johnson & Johnson: Defining the future of healthcare
The executive management team of this “132-year-old startup” company is excited about a future that lies beyond the intersection of science and technology.
Top 200 Medicines Annual Report 2018: Blockbusters thriving despite tumultuous climate
There were as many billion-dollar brands in 2017 as there have been in any other calendar year despite the cratering effects of massive patent cliffs in 2012 and 2015.
Annual Report 2018: State of the Bio Industry
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
2018 Annual Report: Healthcare Communications Agencies Overview – A Year Of Steady Successes
2017 was a very good year for many of the agencies profiled in this annual directory featuring the leading healthcare communications agencies. Some reported individual setbacks, but they were still able to overcome these. As a wave of new drugs and biologics hit the market, several of the top healthcare agencies supported their launches.
Top 10 Pipelines 2018 Annual Report
Deal activity is rampant as Big Pharma gobbles up next-generation medicines and technologies to help overcome maturing pipelines and biosimilar threats.
Healthcare Agency Roundtable 2017
Executives from 2017 Manny Award winners/finalists and other healthcare communications agencies participated in this Q&A forum of industry topics.
2017 Annual Report: Top 50 Companies – The Corner Turned
For the pharmaceutical industry, 2016 brought new blockbusters onto the market to ease the pain of patent expirations.
2017 Annual Report – Top 200 Medicines: Humira Remains Atop The Throne
AbbVie’s biologic therapy Humira for autoimmune disorders continues to dominate the sales landscape; Gilead’s once-daily hepatitis C treatment Harvoni in 2016 repeated its performance as the world’s second-best-selling prescription medicine.
2017 Annual Report: State Of The Bio Industry
R&D success and M&A activity loom as large swing factors for the bio sector in 2017 with the regulatory arena potentially at its most amenable for years.
Ad Right Top
MedAdNews
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.
October 2018 Focus: Top 50 Pharma, Company of the Year and more!